Kaleido Biosciences, Inc. – NASDAQ:KLDO

Add to watchlist

+0.00

+39900%

Market closed

Open in about 13 hours

-100.00%

month

-100.00%

quarter

-100.00%

year

Market Cap	421.96K
Enterprise value	N/A

P/E	N/A
EV/Sales	-36.47
EV/EBITDA	0.26
Price/Sales	0.01
Price/Book	N/A
PEG ratio	N/A
EPS	N/A

Revenue	N/A
EBITDA	N/A
Income	N/A
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	-14752.94%
Oper. margin	-14324.67%
Gross margin	0%
EBIT margin	-14324.67%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Kaleido Biosciences, Inc. (NASDAQ:KLDO): Profit margin
Dec 2022	0	0
Mar 2023	0	0
Jun 2023	0	0
Sep 2023	0	0

Kaleido Biosciences, Inc. (NASDAQ:KLDO): Debt to assets
Dec 2021	50137000	39.53M	78.84%
Mar 2023	0	0
Jun 2023	0	0
Sep 2023	0	0

Kaleido Biosciences, Inc. (NASDAQ:KLDO): Cash Flow
Dec 2022	0	0	0
Mar 2023	0	0	0
Jun 2023	0	0	0
Sep 2023	0	0	0

Kaleido Biosciences alternative data

Kaleido Biosciences, Inc. (NASDAQ:KLDO): Employee count
Aug 2023	76
Sep 2023	76
Oct 2023	76
Nov 2023	76
Dec 2023	76
Jan 2024	76
Feb 2024	76
Mar 2024	76
Apr 2024	76
May 2024	76
Jun 2024	76
Jul 2024	76

Kaleido Biosciences
Insider Trading

Kaleido Biosciences, Inc. (NASDAQ:KLDO): Insider trades (number of shares)
Period	Buy	Sel
Jun 2020	6033333	0
Feb 2021	450000	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	8 Feb 2021	FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC 10 percent o.. 10 percent owner	Common Stock	215,000	$11.5	$2,472,500
Purchase	8 Feb 2021	MENICHELLA DANIEL L director, officer: Chief Executive Off.. director, officer: Chief Execut..	Common Stock	20,000	$11.5	$230,000
Purchase	8 Feb 2021	FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC 10 percent o.. 10 percent owner	Common Stock	215,000	N/A	N/A
Purchase	4 Jun 2020	FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC 10 percent o.. 10 percent owner	Common Stock	2,000,000	$7.5	$15,000,000
Purchase	4 Jun 2020	MELAS KYRIAZI THEO director director	Common Stock	33,333	$7.5	$249,998
Purchase	4 Jun 2020	FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC 10 percent o.. 10 percent owner	Common Stock	2,000,000	N/A	N/A
Purchase	4 Jun 2020	FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC 10 percent o.. 10 percent owner	Common Stock	2,000,000	$7.5	$15,000,000
Purchase	4 Mar 2019	FLAGSHIP VENTURES FUND V GENERAL PARTNER LLC director, 10 .. director, 10 percent owner	Common Stock	933,333	$15	$13,999,995
Purchase	28 Feb 2019	BONNEY MICHAEL W director director	Common Stock	71,520	$14.3	$1,022,736

KLDO insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application OLIGOSACCHARIDE COMPOSITIONS AND METHODS OF USE Filling date: 8 May 2020 Issue date: 28 Jul 2022	8 May 2020	28 Jul 2022
Application	Application GLYCAN PREPARATIONS AND METHODS OF USE FOR HYPERAMMONEMIA Filling date: 3 Nov 2018 Issue date: 28 Jul 2022	3 Nov 2018	28 Jul 2022
Grant	Grant Utility: Glycan therapeutics and method of treating conditions associated with TMAO Filling date: 26 May 2020 Issue date: 25 Jan 2022	26 May 2020	25 Jan 2022
Application	Application GLYCAN THERAPEUTIC COMPOSITIONS AND RELATED METHODS THEREOF Filling date: 30 Jun 2021 Issue date: 30 Dec 2021	30 Jun 2021	30 Dec 2021
Application	Application METHODS OF QUANTIFYING OLIGOSACCHARIDE PREPARATIONS Filling date: 8 Nov 2019 Issue date: 23 Dec 2021	8 Nov 2019	23 Dec 2021
Application	Application OLIGOSACCHARIDE PREPARATIONS AND COMPOSITIONS Filling date: 8 Nov 2019 Issue date: 23 Dec 2021	8 Nov 2019	23 Dec 2021
Grant	Grant Utility: Oligosaccharide compositions and methods of use thereof Filling date: 25 Jan 2021 Issue date: 9 Nov 2021	25 Jan 2021	9 Nov 2021
Application	Application OLIGOSACCHARIDE COMPOSITIONS AND METHODS OF USE THEREOF FOR REDUCING AMMONIA LEVELS Filling date: 21 Aug 2019 Issue date: 1 Jul 2021	21 Aug 2019	1 Jul 2021
Application	Application OLIGOSACCHARIDE COMPOSITIONS AND METHODS OF USE THEREOF Filling date: 25 Jan 2021 Issue date: 3 Jun 2021	25 Jan 2021	3 Jun 2021
Application	Application GLYCAN COMPOSITIONS AND METHODS OF USE Filling date: 13 Jul 2018 Issue date: 3 Jun 2021	13 Jul 2018	3 Jun 2021

Kaleido Biosciences
Earnings Call Transcripts

Quarter	Transcript
Q1 2020 15 May 2020	Q1 2020 Earnings Call Transcript

KLDO earnings call transcripts

Kaleido Biosciences
Executives

Insider	Age	Since	Compensation
Mr. William E. Duke Jr. (1972) Chief Financial Officer	53		$672,870
Mr. Daniel L. Menichella B.A., M.B.A. (1959) Pres, Chief Executive Officer & Director	66		$598,720

Kaleido Biosciences
Latest News

Thursday, 14 April 2022
09:30	Best Penny Stocks to Buy? 3 to Watch as Musk Offers $43B for TWTR	PennyStocks
Wednesday, 13 April 2022
12:05	Dear KLDO Stock Fans, Mark Your Calendars for April 28	InvestorPlace
09:28	Best Penny Stocks to Buy? 3 to Watch as ATRS Stock Explodes	PennyStocks
Friday, 8 April 2022
12:27	Kaleido Biosciences Shares Plunging To 52-Week Low, Read Why	Benzinga
Wednesday, 23 March 2022
12:47	ORIC Stock Plunges on Discontinuation of Oncology Candidate	Zacks Investment Research
Friday, 4 February 2022
11:29	Here's Why Kaleido Biosciences, Inc. (KLDO) is Poised for a Turnaround After Losing 33.2% in 4 Weeks	Zacks Investment Research
Friday, 21 January 2022
11:04	Kaleido Biosciences to Present Updated Data of KB295 In Ulcerative Colitis at the 2022 Crohn's and Colitis Congress	GlobeNewsWire
Wednesday, 5 January 2022
08:28	Kaleido Biosciences, Inc. (KLDO) Sees Hammer Chart Pattern: Time to Buy?	Zacks Investment Research
Monday, 1 November 2021
10:43	Here's Why Kaleido Biosciences, Inc. (KLDO) Is a Great 'Buy the Bottom' Stock Now	Zacks Investment Research
09:57	Kaleido Biosciences, Inc. (KLDO) Reports Q3 Loss, Misses Revenue Estimates	Zacks Investment Research
Thursday, 28 October 2021
11:28	Down 23.6% in 4 Weeks, Here's Why Kaleido Biosciences, Inc. (KLDO) Looks Ripe for a Turnaround	Zacks Investment Research
Tuesday, 12 October 2021
07:30	Kaleido Biosciences to Participate in the Jefferies Virtual Next Generation IBD Therapeutics Summit	GlobeNewsWire
Sunday, 3 October 2021
10:45	5 Penny Stocks To Watch This Week With Potential Biotech Catalysts	PennyStocks
Wednesday, 29 September 2021
07:30	Kaleido Biosciences to Host Virtual R&D Presentation to Discuss Clinical Data and Pipeline Advancement on October 5, 2021	GlobeNewsWire
Thursday, 2 September 2021
07:30	Kaleido Biosciences to Participate in the Morgan Stanley 19th Annual Virtual Global Healthcare Conference	GlobeNewsWire

Frequently Asked Questions (FAQ)

What's the price of Kaleido Biosciences stock today?

One share of Kaleido Biosciences stock can currently be purchased for approximately $0.
When is Kaleido Biosciences's next earnings date?

Unfortunately, Kaleido Biosciences's (KLDO) next earnings date is currently unknown.
Does Kaleido Biosciences pay dividends?

No, Kaleido Biosciences does not pay dividends.
How much money does Kaleido Biosciences make?

Kaleido Biosciences has a market capitalization of 421.96K.
What is Kaleido Biosciences's stock symbol?

Kaleido Biosciences, Inc. is traded on the NASDAQ under the ticker symbol "KLDO".
What is Kaleido Biosciences's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Kaleido Biosciences?

Shares of Kaleido Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Kaleido Biosciences's key executives?
Kaleido Biosciences's management team includes the following people:
- Mr. William E. Duke Jr. Chief Financial Officer(age: 53, pay: $672,870)
- Mr. Daniel L. Menichella B.A., M.B.A. Pres, Chief Executive Officer & Director(age: 66, pay: $598,720)
How many employees does Kaleido Biosciences have?

As Jul 2024, Kaleido Biosciences employs 76 workers.
When Kaleido Biosciences went public?

Kaleido Biosciences, Inc. is publicly traded company for more then 6 years since IPO on 28 Feb 2019.
What is Kaleido Biosciences's official website?

The official website for Kaleido Biosciences is kaleido.com.
Where are Kaleido Biosciences's headquarters?

Kaleido Biosciences is headquartered at 18 Crosby Dr, Bedford, MASSACHUSETTS.
How can i contact Kaleido Biosciences?

Kaleido Biosciences's mailing address is 18 Crosby Dr, Bedford, MASSACHUSETTS and company can be reached via phone at +1 617 674 9000.

Kaleido Biosciences, Inc.

kaleido.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

+1 617 674 9000

18 Crosby Dr
Bedford, MASSACHUSETTS 02421

CIK: 0001751299
ISIN: US4833471000
CUSIP: 483347100